pubmed-article:11316542 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0441771 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0680190 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0280617 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C1831915 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0332173 | lld:lifeskim |
pubmed-article:11316542 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
pubmed-article:11316542 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:11316542 | pubmed:dateCreated | 2001-4-24 | lld:pubmed |
pubmed-article:11316542 | pubmed:abstractText | To investigate whether the addition of weekend chemotherapy consisting of carboplatin/etoposide to hyperfractionated radiation therapy (Hfx RT) and concurrent daily carboplatin/etoposide offers an advantage over the same Hfx RT/daily carboplatin/etoposide. | lld:pubmed |
pubmed-article:11316542 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11316542 | pubmed:language | eng | lld:pubmed |
pubmed-article:11316542 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11316542 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11316542 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11316542 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11316542 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11316542 | pubmed:month | May | lld:pubmed |
pubmed-article:11316542 | pubmed:issn | 0360-3016 | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:JeremicBB | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:ShibamotoYY | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:Radosavljevic... | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:AcimovicLL | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:Milisavljevic... | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:MilicicBB | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:NikolicNN | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:Aleksandrovic... | lld:pubmed |
pubmed-article:11316542 | pubmed:author | pubmed-author:DagovicAA | lld:pubmed |
pubmed-article:11316542 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11316542 | pubmed:day | 1 | lld:pubmed |
pubmed-article:11316542 | pubmed:volume | 50 | lld:pubmed |
pubmed-article:11316542 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11316542 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11316542 | pubmed:pagination | 19-25 | lld:pubmed |
pubmed-article:11316542 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:meshHeading | pubmed-meshheading:11316542... | lld:pubmed |
pubmed-article:11316542 | pubmed:year | 2001 | lld:pubmed |
pubmed-article:11316542 | pubmed:articleTitle | Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. | lld:pubmed |
pubmed-article:11316542 | pubmed:affiliation | Department of Oncology, University Hospital, Kragujevac, Yugoslavia. bjeremic@med.uni-tuebingen.de | lld:pubmed |
pubmed-article:11316542 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11316542 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:11316542 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:11316542 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11316542 | lld:pubmed |